Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs …

Jul 27, 2022 · BIOCON GROUP “We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics …

CouponFollow Extension

23%
OFF

Biocon Q1FY23 Revenue At Rs 2,217 Cr, Up 23%; Net Profit At Rs …

2 weeks from now

Jul 27, 2022 · BIOCON GROUP “We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics …

biocon.com

29%
OFF

Biocon Quarterly Revenues For Biosimilars Up 29%

2 weeks from now

Jul 28, 2022 · The revenues for the parent company improved by Rs 2217 Crore ($278 million) year over year. Biocon’s net profit went up Rs 144 Crore ($18 million), about 71% year over …

centerforbiosimilars.com

71%
OFF

Biocon Q1 Results: Profit Rises 71% YoY To Rs 144 Crore

2 weeks from now

Jul 27, 2022 · Biocon on Wednesday reported 71% year-on-year (YoY) jump in net profit to Rs 144 crore during Q1FY23, driven by sales of biosimilar insulin glargine in the US, despite rise …

indiatimes.com

23%
OFF

Biocon Q1FY23 Revenue Up By 23% At Rs 2,217 Cr | Siliconindia

2 weeks from now

Jul 28, 2022 · Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. "We have had a …

siliconindia.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr

2 weeks from now

Jul 28, 2022 · Biocon Q1FY23 revenue up 23% at Rs 2,217 cr. ... (EBITDA) grew 25 per cent and margin improved to 31 per cent compared to 30 per cent in Q1FY22 and net profit grew 71 per …

webindia123.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Investing.com India

2 weeks from now

Jul 27, 2022 · Read Biocon Q1FY23 revenue up 23% at Rs 2,217 cr By IANS. Biocon Q1FY23 revenue up 23% at Rs 2,217 cr. Download the App. More markets insights, more alerts, more …

investing.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Thenewsmen.co.in

2 weeks from now

Jul 27, 2022 · We have had a strong start to the year. At a consolidated level, YoY revenues grew 23 per cent backed by robust growth in both Biosimilars (29 per cent) and Generics (19 per …

thenewsmen.co.in

5%
OFF

Biocon Buys Back An Investor Stake In Biologics Unit, Posts Rs 25 …

2 weeks from now

Jan 30, 2025 · Biocon's board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected to complete by February 1, …

indiatimes.com

30%
OFF

Biocon Q1FY25 Revenue Up 30% At Rs 4,567 Cr EBITDA Up 117

2 weeks from now

Aug 8, 2024 · Financial Commentary: Q1FY25 . Total Consolidated Revenue for Q1FY25 grew 30% year-on-year (YoY) to Rs 4,567 crore.. Other Income includes proceeds of Rs 1,057 …

biocon.com

23%
OFF

Biocon Q1FY23 Revenue At Rs 2,217 Cr, Up 23%; Net Profit At …

2 weeks from now

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25% Biosimilars Up 29%; Generics Up 19%; Research Services Up …

biocon.com

96%
OFF

Biocon Q3 Results: Profit Plummets 96%; Misses Estimates

2 weeks from now

Jan 30, 2025 · Biocon Ltd.'s Q3FY25 consolidated net profit plummeted 96% to Rs 25 crore, falling short of analysts' estimates. Revenue declined 3.4% to Rs 3,821 crore. Biocon Ltd.'s …

ndtvprofit.com

36%
OFF

Biocon Q3FY23 Revenue At Rs 3,020 Cr, Up 36%; Biosimilars Up …

2 weeks from now

Mar 9, 2023 · EBITDA at Rs 723 Cr, Up 35%; Core EBITDA at Rs 1,069 Cr, Up 49%; Net Profit (excluding exceptional items) at Rs 140 Cr Bengaluru, Karnataka, India: February 14, 2023: …

bioconbiologics.com

23%
OFF

Biocon Q1FY23 Revenue Up 23% At Rs 2,217 Cr - Smetimes.in

2 weeks from now

Global biopharmaceuticals company Biocon on Wednesday reported 23 per cent rise in revenue for the first quarter of financial year 2023, at Rs 2,217 crore. ... Biocon Q1FY23 revenue up …

smetimes.in

18%
OFF

Biocon Q3FY22 Revenue At Rs 2,223 Cr, Up 18%; EBITDA At Rs 537 …

2 weeks from now

Jan 20, 2022 · PBT, excluding the mark- to- market loss related to Adagio investment, stood at Rs 201 Crore, up 82% YoY; Net R&D Expenses at Rs 64 Crore, representing 7% of revenue; …

bioconbiologics.com

38%
OFF

FY23 Revenue At Rs 11,550 Cr, Up 38%; EBITDA At Rs 2,888 Cr …

2 weeks from now

FY23 Revenue at Rs 11,550 Cr, Up 38%; EBITDA at Rs 2,888 Cr, Up 32% Net Profit (before exceptional Items) at Rs 787 Cr, Up 9% Bengaluru, Karnataka, India: May 23, 2023: Biocon …

biocon.com

21%
OFF

Biocon Q4FY22 Revenue At Rs 2,476 Cr, Up 21%; Core EBITDA At …

2 weeks from now

Apr 28, 2022 · PBT before Exceptional Items was Rs 384 Crore (vs. Rs 353 Crore in Q4FY21) Up by 9%; Net Profit before Exceptional Items was Rs 262 Crore (vs. Rs 257 Crore in Q4FY21) …

bioconbiologics.com

17%
OFF

Q3 Results Highlights: Bajaj Holdings' Revenue Up 17% ... - CNBCTV18

2 weeks from now

Jan 30, 2025 · Biocon’s financial performance for Q3 FY25 was in line with expectations.However, the year-on-year comparison is impacted by one-time gains recorded in Q3 FY24. In the …

cnbctv18.com

7%
OFF

Biocon Q3FY25 Revenue At Rs 3,856 Cr, Up 7%# EBITDA At Rs 787 …

2 weeks from now

Jan 30, 2025 · Financial Commentary: Q3FY25. Consolidated Total Revenue for Q3FY25 was at Rs 3,856 crore.Reported 7% YoY growth on a like-for-like basis, after adjusting for Branded …

biocon.com

59%
OFF

Biocon Q4FY23 Revenue At Rs 3,929 Cr, Up 59%; Biosimilars Up …

2 weeks from now

FY23 Revenue at Rs 11,550 Cr, Up 38%; EBITDA at Rs 2,888 Cr, Up 32% Net Profit (before exceptional Items) at Rs 787 Cr, Up 9%. Bengaluru, Karnataka, India: May 23, 2023: Biocon …

biocon.com

FAQs about Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs … Coupon?

How did Biocon Group perform in q1fy22?

BIOCON GROUP “We have had a strong start to the year. At a consolidated level, y-o-y revenues grew 23% backed by robust growth in both Biosimilars (29%) and Generics (19%). Core EBITDA grew 25% and margin improved to 31% compared to 30% in Q1FY22. and Net Profit grew 71% to Rs 144 Crore. ...

What was Biocon's net profit in q3fy25?

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the previous financial year, the company reported a loss of Rs 16 crore. ...

How did Biocon biologics perform in Q3FY23?

Biocon Biologics reported a 54% growth in Q3FY23 with revenues at Rs Rs 1,507 crore. This strong performance was led by a solid showing in global markets and the consolidation of Viatris’ biosimilars business, following the deal close. ...

How did Biocon biologics & Eris Lifesciences perform in q1fy25?

Note: *Q1FY25 Consolidated Revenue includes proceeds of Rs 1057 Cr on account of the strategic collaboration between Biocon Biologics & Eris Lifesciences. “ Biocon has reported consolidated revenues of Rs 4,567 crore for Q1FY25, delivering a strong 30% YoY growth, with EBITDA growing 117% to Rs 1,755 crore and a Net Profit of Rs 660 crore. ...

How will Biocon's R&D investments drive its future growth?

Biocon reported Research Services revenues of Rs 786 crore and Generics business revenues of Rs 718 crore, which grew 23% and 18%, respectively. Net R&D investments amounted to Rs 337 crore this quarter, driven by the advancement of Biocon’s research pipeline. ...

How did Biocon biologics perform in a year?

Biocon Biologics’ revenue for the full year stood at Rs 5,584 Crore, reporting a growth of 61%. EBITDA for the year stood at Rs 1,338 crore, a year-on-year growth of 32%. Core EBITDA grew by 68% to Rs 2,216 crore. ...